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Abstract: Here, we provide a first comparative study of the therapeutic potential of allogeneic 
mesenchymal stem cells derived from bone marrow (BM-MSCs), adipose tissue (AD-MSCs), and 
dental pulp (DP-MSCs) embedded in fibrin matrix, in small (rat) and large (pig) spinal cord injury 
(SCI) models during subacute period of spinal contusion. Results of behavioral, 
electrophysiological, and histological assessment as well as immunohistochemistry and real-time 
polymerase chain reaction analysis suggest that application of AD-MSCs combined with a fibrin 
matrix within the subacute period in rats (2 weeks after injury), provides significantly higher post-
traumatic regeneration compared to a similar application of BM-MSCs or DP-MSCs. Within the rat 
model, use of AD-MSCs resulted in a marked change in: (1) restoration of locomotor activity and 
conduction along spinal axons; (2) reduction of post-traumatic cavitation and enhancing tissue 
retention; and (3) modulation of microglial and astroglial activation. The effect of an autologous 
application of AD-MSCs during the subacute period after spinal contusion was also confirmed in 
pigs (6 weeks after injury). Effects included: (1) partial restoration of the somatosensory spinal 
pathways; (2) reduction of post-traumatic cavitation and enhancing tissue retention; and (3) 
modulation of astroglial activation in dorsal root entry zone. However, pigs only partially replicated 
the findings observed in rats. Together, these results indicate application of AD-MSCs embedded in 
fibrin matrix at the site of SCI during the subacute period can facilitate regeneration of nervous 
tissue in rats and pigs. These results, for the first time, provide robust support for the use of AD-
MSC to treat subacute SCI. 
Keywords spinal cord injury; mesenchymal stem cells; adipose tissue; bone marrow; dental pulp; 
fibrin matrix; rat; pig 
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1. Introduction 
Mesenchymal stem cells (MSCs) have to date been one of the most promising progenitor cell 
types, associated with diverse functional capabilities and extensive tissue regenerative potential. 
MSCs can migrate to areas of injury [1] and integrate with damaged tissues, where they mediate 
immunomodulatory [2–4], antiapoptotic, and anti-inflammatory effects through the secretion of 
various neurotrophic factors and cytokines and signaling pathway activation through specific receptors 
on target cells [5]. These specific features, along with multiple studies reporting the ability of MSCs to 
promote regeneration of nervous tissues in the brain and spinal cord, support the potential of MSCs as 
treatments of neurodegenerative conditions and traumatic brain and spinal cord injury (SCI) [6,7]. 
MSCs with specific immunophenotypic characteristics and differentiation potentials can be 
found in different organs. Bone marrow is the most common source of MSCs (BM-MSCs) used in 
studies of SCI at both preclinical and clinical stages [8]. There are several difficulties associated with 
the isolation of cells from the bone marrow, for example their number and regenerative potential, 
which decreases sharply with age. Another promising source of MSCs is adipose tissue (AD-MSCs), 
which due to the simple method of isolation and purification, alongside more consistent proliferative 
activity, gives AD-MSCs the potential to be more easily clinically translated. Furthermore, AD-MSCs 
were found to be effective in protecting the synaptic stability of motor neurons and in the facilitation 
of antioxidant and anti-inflammatory mechanisms after SCI [9,10]. Dental pulp-derived MSCs (DP-
MSCs) have also been proposed as an alternative to BM-MSCs and AD-MSCs [11,12]. DP-MSCs were 
found to be effective in the protection of sensory and motor neurons after SCI, through the inhibition 
of apoptosis and promotion of axonal growth [13–15]. 
The main features of all MSCs, including their fibroblast-like morphology, growth characteristics 
in culture, ability to differentiate into osteogenic, adipogenic, and chondrogenic lineages, and broad 
profiles of gene expression make them valuable tools for neuroregenerative studies [16–20]. However, 
a comparative analysis of the regenerative potential of MSCs obtained from different sources indicates 
there are differences. BM-MSCs have greater chondrogenic and osteogenic potentials, with a similar 
colony efficiency to AD-MSCs, but lack the biological advantages of AD-MSCs when comparing 
proliferative capacity and immunomodulatory effects [21–23]. DP-MSCs, in turn, have a significantly 
greater cytoprotective effects compared to BM-MSCs [24]. We hypothesize that differences in the 
features of MSCs due to tissue origin and donor-related variations in regenerative potential determine 
the overall regenerative and protective effects seen when applied as a treatment for SCI. 
Systemic, intraspinal, and intrathecal routes of administration of cell-based treatments have 
several drawbacks. These drawbacks are primarily associated with limited injection volumes, low 
stem cell viability in situ, and side effects. Biopolymer matrices are commonly used to maintain 
transplanted cells and optimize the microenvironment to increase cell survival and to control 
distribution of the bioactive molecules released by the implanted cells [25–27]. The combined 
application of MSCs with such a matrix could provide a safe and effective approach for cell 
transplantation into humans with SCI [7,26,28]. 
Preclinical studies of cell-based therapies commonly utilize small laboratory animals (rats, mice) 
as models, with reported structural and functional restoration of damaged tissue. However, 
translation of the results to clinical trials do not always produce the same effect in humans, often due 
to structural differences between humans and small animals, as well as variations in physiological 
characteristics, mechanisms of disease development, and the inability to perform autologous 
transplantation [29–31]. Preclinical studies performed in larger animal models (for example pigs and 
monkeys) may circumvent some of these issues, as these species share more anatomical and 
functional similarities with humans. The use of larger animal models may facilitate better translation 
to human clinical trials, minimizing economic risks. 
A major gap in the knowledge required for the successful translation of preclinical studies is the 
absence of adequate comparisons between different animal models, particularly between commonly 
used small and large species within the same study. To address this critical gap, we compared the 
therapeutic potential of allogeneic BM-MSCs, AD-MSCs, and DP-MSCs embedded in fibrin matrix 
(FM) in both rat and pig models of spinal cord contusion. Our results indicate that in the rat model 
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of the subacute period of spinal contusion, AD-MSCs have a better neuroregenerative potential 
compared to MSCs from other tissue origins, based on criteria scoring functional recovery, tissue 
retention, reduction of post-traumatic cavitation, modulation of microglial and astroglial activation, 
and neuroprotection. Application of AD-MSCs in the subacute period of SCI in pigs also showed 
significant differences based on behavioral evaluation, with some improvement in the restoration of 
the somatosensory pathways, tissue retention, reduction of post-traumatic cavitation, and 
predominant modulation of astroglial activation in dorsal root entry zone. 
2. Materials and Methods 
The methods described herein were approved by the Kazan Federal University Animal Care and 
Use Committee (Permit Number 2, 5 May 2015) and experimental protocols were consistent with the 
guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care 
International and Physiological Section of the Russian National Committee on Bioethics. All studies 
were designed to minimize animal numbers and the severity of procedures. Study designs are 
illustrated in Figure 1. 
2.1. Isolation and Culture of Mesenchymal Stem Cells 
For all cultured cells, the medium was replaced every 3 days. At passage 3, the cells were used 
for the subsequent experiments. MSCs were derived from the adipose tissue, bone marrow and 
dental pulp of female Wistar rats (weighing 250–300 g each; Pushchino Laboratory, Pushchino, 
Russia) and adipose tissue from 4-month-old female pot-bellied pigs (9–12 kg) followed isolation and 
characterization [32]. 
2.1.1. Rat AD-MSCs  
Rat adipose tissue was collected aseptically in an operating room. Further manipulations were 
carried out in a cell culture laboratory as previously described [32]. The adipose tissue was minced, 
purified by centrifugation, and digested with a 0.2% crab hepatopancreas collagenase (Biolot, St. 
Petersburg, Russia) at 37 °С for 1 h with agitation. The homogenate was centrifuged and the 
enzymatic solution was decanted. The cell pellet was suspended with a Dulbecco’s phosphate-
buffered saline (DPBS, PanEco, Moscow, Russia) solution and centrifuged to remove residual 
enzymes. The obtained cells were cultured in α-MEM medium with 10% fetal bovine serum (FBS), 
100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine (all obtained from PanEco). 
2.1.2. Rat BM-MSCs  
BM-MSCs were collected from femurs. Briefly, normal regular Wistar rats were sacrificed, and 
their femurs were removed with surgical scissors. After removal of removal of residual soft tissue, 
epiphyses of the femurs were cut and the marrow was collected by flushing the canals with DPBS. 
The flushed solution was collected in 50 mL sterile tube and centrifuges 5 min at 500× g, after which 
the supernatant was removed. The cell pellet was resuspended in cultural medium, containing 
DMEM, 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine, and 
thoroughly homogenized. Cells were seeded into culture flasks and incubated for 24 h under 
standard conditions (37 °С and 5% CO2); the non-adherent cells were removed by replacing the 
culture medium. 
2.1.3. Rat DP-MSCs 
DP-MSCs were harvested using a previously reported method [33]. Briefly, extracted teeth were 
removed and placed in sterile PBS containing 100 U/mL penicillin and 100 mg/mL streptomycin. The 
pulp was removed from the cavity, washed in sterile PBS, and minced with ophthalmology scissors. 
Centrifugation at 2000× g for 5 min, was used to pellet the cells. The supernatant was discarded and 
the cells were resuspended in 2.5 mL of culture medium (α-MEM, 10% FBS, 100 μM L-ascorbic acid 
2-phosphate (Sigma-Aldrich, St. Louis, MI, USA), 2 mM L-glutamine, 100 U/mL penicillin, and 100 
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mg/mL streptomycin). Cells were seed into culture flasks and incubated at 37 °С and 5% CO2 for 3 
days, avoiding any movement that may displace the cells. 
2.1.4. Pig MSCs  
Pig adipose tissue was collected aseptically from the subcutaneous fat of 4-month-old female 
pot-bellied pigs under anesthesia (propofol (2–6 mg/kg) via endotracheal intubation and maintained 
with isoflurane (1.3%)). Infiltration of the subcutaneous tissue was performed with a solution (total 
volume 200–300 mL) containing 1 mL of epinephrine hydrochloride (1 mg/mL) in 200 mL 0.9% NaCl. 
A small skin incision was made to a length of 0.5–1 cm, then the adipose tissue was cannulated by an 
endoscopic cannula (Eleps, Kazan, Russia, diameter 3 mm). The liquid and fat deposits were removed 
by vacuum extraction and subcutaneous fat collected in sterile 50 mL tubes containing 0.9% NaCl 
solution and delivered to the culture laboratory for subsequent cultivation. 
The obtained subcutaneous fat was centrifuged at 500× g for 5 min, after which the supernatant 
was removed. The adipose tissue was thoroughly homogenized with sterile scissors and 0.9% NaCl 
solution was added. The centrifugation was repeated and the supernatant was removed. A freshly 
prepared sterile solution 0.2% crab hepatopancreas collagenase was added to the adipose tissue 
homogenate and incubated at 37 °С for 1 h with shaking. Then, the homogenate was centrifuged at 
500× g for 5 min and the supernatant removed. Resulting cells (of stromal vascular fraction of adipose 
tissue) were seeded into culture flasks and cultivated in medium containing DMEM, 20% FBS, 2 mM 
L-glutamine, 100 μM L-ascorbic acid 2-phosphate, 100 U/mL penicillin, and 100 mg/mL streptomycin 
at 37 °С and 5% CO2. After 24–48 h, the non-adherent cells were removed by replacing the culture 
medium. 
2.2. Lentiviral Transduction of MSCs 
The MSCs at passage 0 were transduced with lentiviral vectors encoding enhanced green 
fluorescent protein (EGFP) (AD-MSCs + LV-EGFP, BM-MSCs + LV-EGFP, DP-MSCs + LV-EGFP) as 
previously described [7]. The percentages of EGFP-positive cells were assessed by flow cytometry 
(Guava EasyCyte 8HT, Millipore, MA, USA). After viral transduction, the MSCs, regardless or origin, 
typically begin to express EGFP within 48 h, with a plateau of expression reached at 96 h and 74 ± 5% 
of the MSCs in each population studied being EGFP-positive. 
2.3. Flow Cytometry of MSCs 
The cells were trypsinized and washed in PBS twice, pelleting cells after each wash by 
centrifugation at 500× g for 3 min. Cells were incubated with primary antibodies for 1 h at room 
temperature (RT) (Table 3). Subsequently, cells were washed three times with PBS, centrifuging at 
500× g for 3 min to pellet the cells between washes, and incubated with secondary antibodiesfor a 
further 1 h at RT. After staining, the cells were fixed in 10% paraformaldehyde (PFA, Sigma-Aldrich) 
for 30 min and washed twice in PBS as detailed above. Cells were analyzed using a flow cytometer 
FACS Aria III (BD Biosciences, San Jose, CA, USA). The cells obtained from five animals were 
analyzed in each group, data are provided in Section 3. 
2.4. Animals and Investigated Groups 
Figure 1 provides a design of experiments in rats and pigs. 
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Figure 1. Study design in rodent and porcine models. (A) For experiments in rats, mesenchymal stem 
cells derived from bone marrow (BM-MSCs), adipose tissue (AD-MSCs), and dental pulp (DP-MSCs) 
were isolated, transduced by lentiviral vectors encoding enhanced green fluorescent protein (LV-
EGFP) at passage 0 and cultivated up to passage 3. Two weeks after spinal cord injury (SCI) the 
obtained cells embedded in fibrin matrix (FM) were used for allogenic application into the area of injury. 
(A1–A3) Lower panels illustrate EGFP+-cells at day 14 after application of AD-MSCs, BM-MSCs, and 
DP-MSCs, transduced by LV-EGFP, in dorsal root entry zone (DREZ). Scale bar: 5 μm. (B) For 
experiments in pigs, AD-MSCs were isolated, transduced by LV-EGFP at passage 0 and cultivated up 
to passage 3. Six weeks after SCI the obtained cells embedded in FM were used for autologous 
application into the area of injury. (B1,B2) Lower panels illustrates EGFP+-cells at day 14 after application 
of AD-MSCs, transduced by LV-EGFP, in DREZ. The area marked in B1 with dashed boxed areas; 
corresponds to the enlarged image B2. Scale bars: 50 (B1) and 10 (B2) μm. 
2.4.1. Rats 
One hundred fifteen adult female Wistar rats were randomly assigned to five groups. Allogenic 
MSCs + LV-EGFP, 1 × 106 cells per rat, mixed with FM Tissucol (18 μL, Baxter, Deerfield, IL, USA) 
were applied on top of the injury through 2 weeks after SCI. The groups were: (1) FM + AD-MSCs + 
LV-EGFP, n = 25; (2) FM + BM-MSCs + LV-EGFP, n = 25; (3) FM + DP-MSCs + LV-EGFP, n = 25; (4) 
FM applied only, n = 25; and (5) without SCI (intact control, n = 15). All animals were evaluated by 
behavioral and electrophysiological assessment. Ten animals in each experimental group and seven 
in the intact control group were randomly selected for histology/immunohistochemistry and RT-PCR 
analysis. Animals were housed per group in clear plastic cages (12 h:12 h light/dark cycle) with food 
and water available ad libitum. 
2.4.2. Pigs  
Seventeen healthy 4-month-old female pot-bellied pigs (9–12 kg) were used in this study. All 
pigs were clinically judged to be in good health and to have a normal neurological status. Autologous 
AD-MSCs + LV-EGFP, 8 × 106 cells per pig, mixed with FM Tissucol (150 μL) was applied on top of 
the injury through 6 weeks after SCI. The groups were: (1) FM + AD-MSCs + LV-EGFP, n = 5; (2) FM 
applied only, n = 5; and (3) without SCI (intact control, n = 5). Two additional pigs were used to 
evaluate the distribution of AD-MSCs in the area of SCI at day 14 after application. 
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2.5. Surgical Procedures 
2.5.1. Rats  
Rat SCI and cell application were carried out as previously described [7]. Rats were deeply 
anesthetized under general anesthesia with isoflurane and laminectomy at the Th8 vertebral level 
was performed. Zoletil (20 mg/kg, Virbac Sante Animale, France) was used by intramuscular injection 
for analgesia. Moderate spinal cord contusion was induced with an impact rod (2 mm diameter, 10 
g) and a custom-made weight drop device (impactor) [7], which centered at the Th8 and dropped 
from 25 mm height. After SCI, the wound was sutured in layers. Following surgery, the rats had 
intramuscular injections of gentamicin (25 mg/kg, Microgen, Moscow, Russia) for 7 consecutive days. 
The injured rats’ bladders were manually emptied twice daily until spontaneous voiding occurred. 
The skin was re-incised to expose the spinal cord 2 weeks after SCI (subacute period). After 
removing synechiae and making several longitudinal notches in the dura mater, FM with or without 
MSCs were applied on top of the injury and the dorsal back muscles and the skin were sutured. After 
surgery, the rats received daily intramuscular doses of gentamicin (25 mg/kg) for 7 consecutive days. 
After the operation, the rats were monitored and following evaluation showed consistent and similar 
changes in motor performance on both legs. For cell application, we strictly selected the spinal cord 
contusion model that showed complete hind limb paralysis. 
2.5.2. Pigs  
After intramuscular injection of xylazine (0.6 mg/kg) and ketamine (5 mg/kg), anesthesia was 
induced with propofol (2–6 mg/kg) and maintained with isoflurane (1.3%) during the operation. 
Laminectomy was performed at vertebral level Th10 and spinal cord contusion was induced by 
impact rod (7 mm diameter, 50 g) from 20 cm height, followed by 10 min of compression [34]. Due to 
the expected variation in spinal cords in pigs, X-ray assessment of thoracic and lumbar levels was 
performed to identify the same level for SCI across all animals. To approximate the degree of damage 
to a human SCI, sustained compression was carrying out (10 min) in addition to contusion to mimic 
prolonged spinal compression commonly found in traumatic SCI in human [34]. Following injury, 
the back muscles and the skin were sutured in layers. A urinary catheter (10 Fr, Jorgensen 
Laboratories Inc., Loveland, CO, USA) was manually inserted for postinjury bladder drainage and 
removed 3–5 days after SCI, after which the animals were able to reflexively empty their bladders. 
Animals were given cefazolin (25 mg/kg, Sintez, Kurgan, Russia) and ketoprophen (1 mg/kg, AVZ, 
Moscow, Russia) via intramuscular injection after surgery and for 5 days, and were fasted for at least 
12 h after surgery. Pigs were housed individually for the first 48 h, after which they were housed in 
pairs. 
Under general anesthesia, the skin was re-incised to expose the spinal cord 6 weeks after SCI in 
pigs (subacute period). The selection of the subacute period of cell transplantation was due to the 
technical possibility of carrying out autologous MSCs transplantation in a clinical practice, when 
there are surgical indications for reoperation, during which it is possible to apply MSCs obtained 
from a patient in an acute period and cultivate to the required amount. After removing synechias and 
making several longitudinal notches in the dura mater (2–3 notches, 1–2 mm length), FM with or 
without MSCs were applied on top of the injured spinal cord. The wound was sutured and pigs 
received intramuscular doses of cefazolin (25 mg/kg) and ketoprophen (1 mg/kg) for 5 days. 
2.6. Behavioral Assessment 
All behavioral studies were scored simultaneously by two observers who were blinded to the 
treatment groups. Final scores were obtained by averaging the two scores awarded by the examiners. 
2.6.1. Rats  
Motor function was evaluated using the open-field Basso, Beattie, Bresnahan (BBB) [35] 
locomotor rating scale. The baseline was obtained at 3 days before SCI. BBB rating scale defines three 
Biomolecules 2019, 9, 811 7 of 28 
 
phases for the recovery of voluntary movements after spinal cord contusion: early (scores of 0–7), 
intermediate (scores of 8–13), and late (scores of 14–21). To evaluate differences in functional 
recovery, a behavioral assessment in the experimental groups was performed before SCI, on day 1, 
and once a week up to 11 weeks after SCI. 
2.6.2. Pigs  
For assessment of the motor function restoration in pigs, the Porcine Thoracic Injury Behavioral 
Scale (PTIBS) was used [34]. PTIBS is a 10-point scale, where the lowest scores (1–3) describe varying 
degrees of “dragging”, and the highest scores (7–10) describe walking behavior. Videotaping of 
locomotor recovery in the experimental groups was performed before SCI, on day 3, and once a week 
up to 22 weeks after SCI. All pigs were walking through a 50-m-long corridor within a 15 min time-
period, while recorded on video camera. 
2.7. Electrophysiological Studies 
Electrophysiological tests were performed under anesthesia on intact rats and experimentally 
injured rats at 2 and 11 weeks after SCI as previously described [7,36]. Electrophysiological tests were 
performed under anesthesia on experimental pigs before the injury, at 15 min, and at 6 and 22 weeks 
after SCI. The M- and H-waves (pigs only have M-response) from the tibialis anterior muscle in pigs 
and the gastrocnemius muscle in rats were recorded in response to stimulation of the sciatic nerve 
[37,38]. 
Monopolar needle electrodes were used for recording. An active electrode was inserted into the 
middle of the muscle belly and the reference electrode was implanted within a region of the 
tendomuscular junction. Electrical stimulation of the sciatic nerve was performed with square-wave 
single stimuli and a pulse width of 0.2 ms. A skin electrode with fixed electrode spacing and 
monopolar needle electrodes inserted subcutaneously within an area where the sciatic nerve exits 
from the pelvis were used for stimulation in pigs and rats, respectively [39]. 
Transcranial electrical stimulation (TES) was carried out for registration of motor evoked 
potentials (MEPs) recorded by subcutaneous needle electrodes in tested muscles. The recording 
electrodes remained in the tibialis anterior muscle or the gastrocnemius muscle. TES was performed 
by needle electrodes inserted under the scalp up to the contact with the bone of the skull. The cathode 
was placed in the middle, approximately 0.5 cm caudally from the interorbital line, and the anode 
was placed in the middle near the occipital bone. Duration of stimuli ranged from 0.04 (rats) to 0.1 
(pigs) ms, with an intensity from 20 to 500 V. An average of three repetitions and close in latency 
responses were analyzed and compared. 
Somatosensory evoked potentials (SEPs) were registered by monopolar needle electrodes 
inserted subcutaneously for evaluation of conduction across the posterior columns of the spinal cord. 
An active electrode was inserted over upper lumbar vertebrae and a reference electrode was inserted 
over middle thoracic vertebrae for registration from lumbar level. The cathode electrode was also 
inserted in the middle, approximately 0.5 cm caudally from the interorbital line in rats and over the 
vertex in pigs, and the anode electrode in the middle near the occipital bone in rats and over the snout 
in pigs for registration from scalp. Electrical stimulation was performed using round electrodes in 
rats. Stimulation of the tibial nerve in the medial malleolus area was performed with a cutaneous 
stimulating electrode with a fixed interelectrode distance in pigs. Rectangular electric stimuli 0.2 ms 
with frequency of 3 Hz were used. The stimulus intensity was chosen based on the tail movements 
in rats and foot muscles in pigs (smallest stimulus producing tail movements was used). An average 
of three repetitions and close in latency responses were analyzed and compared. 
2.8. Histology and Immunohistochemistry 
At 7, 14, 30 and 60 days after reoperation, rats were anesthetized and subjected to intracardiac 
perfusion with 4% PFA (4 °С). Spinal cord pieces (50 mm segment centered around the injury site) 
were removed, fixed in 4% PFA at 4 °C overnight and incubated in 30% sucrose. At 2 and 16 weeks 
Biomolecules 2019, 9, 811 8 of 28 
 
after reoperation, pigs were deeply anesthetized and transcardially perfused with 4% PFA (4 °С). An 
8 cm segment of thoracic spinal cord centered around the injury site was collected, fixed in 4% PFA 
for 48 h, divided into 1-cm blocks in length and cryoprotected in 15% and 30% sucrose. Samples were 
embedded in tissue freezing medium (Tissue-Tek O.C.T. Compound, Sakura, Torrance, CA, USA) 
and then 20 μm transverse tissue sections were obtained using the cryostat Microm HM 560 (Thermo 
Scientific, Waltham, MA, USA). 
A series of cross-sections obtained at day 60 in rats and week 16 in pigs after reoperation were 
used. Tissue sections prepared from spinal cord regions just 5 mm rostral and caudal to the injury 
epicenter were stained with Azur-eosin (MiniMed, Syponevo, Russia). Images were then captured 
with a light scanning microscope APERIOCS2 (Leica, Allendale, NJ, USA). The cross-sectional area 
of the spared tissue and abnormal cavities was measured. A total area of abnormal cavities in the 
spinal cord cross-section was calculated by counting cysts with an area of not less than 1.500 μm2. 
Aperio ImageScope software 12.4 (Leica) was used to measure the tissue area. 
For immunofluorescence staining, sections were blocked with 5% normal goat serum for 1 h at 
RT and then incubated with primary antibodies overnight at 4 °C (Table 1). For visualization, 
fluorophore-conjugated secondary antibodies were applied for 2 h at RT. After washing, 4′,6-
diamidino-2-phenylindole (DAPI) (10 μg/mL in PBS, Sigma) was used to visualize the nuclei. 
Coverslips were mounted on slides using mounting medium (ImmunoHistoMount, Santa Cruz, 
Dallas, TX, USA) and the stained sections were examined using an LSM 780 Confocal Microscope 
(Carl Zeiss, Jena, Germany). Using the Zen 2012 Software (Carl Zeiss) we analyzed the total intensity 
of GFAP and Iba1 (semiquantitative analysis) at 5-mm increments extending from the contusion 
center of the SCI. All sections were imaged using identical confocal settings (laser intensity, gain, and 
offset). The areas selected for a semiquantitative immunohistochemical evaluation as previously 
described were the ventral horns (VH), the dorsal corticospinal tract (CST, except the pigs), ventral 
funiculi (VF), the area around the central canal (CC), and the dorsal root entry zone (DREZ) ([40]). 
The analysis was not carried out in the CST area in pigs due to the presence of cavities in this site in 
control group after application of FM only. 
Table 1. Primary and secondary antibodies used in flow cytometry and immunofluorescence staining. 
Antibody Host Dilution Source 
Thy-1 (CD90) conjugated with РЕ/Су5 Mouse 1:100 Вiolegend 
CD 73 Rat 1:100 Вiolegend 
CD 44 conjugated with APC/Cy7 Rat 1:100 Вiolegend 
CD 29 conjugated with РЕ Hamster 1:100 Вiolegend 
CD34 Mouse 1:100 Santa Cruz 
CD45 Rat 1:100 Sony 
GFAP Mouse 1:200 Santa Cruz 
Iba1 Goat 1:300 Abcam 
Anti-goat IgG conjugated with 
Alexa 555 
Donkey 1:200 Invitrogen 
Anti-mouse IgG conjugated with Alexa 546 Donkey 1:200 Invitrogen 
2.9. Real-Time PCR 
Total RNA was isolated from fresh rat spinal cords (5-mm-long segment encompassing the 
injury site) using a modified phenol/chloroform extraction and Yellow Solve Kit (Silex, Moscow, 
Russia) according to the manufacturer’s recommendations. Gene-specific primers and probes were 
designed and the selected sets of primers/probes were blasted against the GenBank to confirm their 
species and gene specificity. First strand cDNA synthesis was performed using 100 ng of total RNA, 
100 units of RevertAid reverse transcriptase (Thermo Fisher Scientific), 100 pmol of random hexamer 
primers and 5 units of RNAse inhibitor according to the recommended manufacturer’s protocol. A 
quantitative analysis of mRNA of 18S, Gfap, Vimentin, S100, Pdgfα, Pdgfβ, Vegf, Fgf2, Hspa1b, CNPase, 
Ngf, Iba1, Mpz, Olig2, Caspase3, Mbp, and Gap-43 genes was performed using CFX 96 Real-Time PCR 
System (Bio-Rad, Hercules, CA, USA). We analyzed 100 ng of cDNA for expression of target genes, 
using 2.5× Reaction Mixture B (Syntol, Moscow, Russia), 200 nM of each primer and 100 nM probe 
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(Supplementary Table S1). The mRNA expression was normalized using 18S rRNA. Plasmid DNA 
with corresponding inserts were used to perform standard curves. The mRNA level in intact spinal 
cord at Th8 level was considered as 100%. All RT-PCRs were performed in triplicate. 
2.10. Cytokine Assay 
Multiplex analyses based on the xMAP Luminex technology were performed using MILLIPLEX 
MAP Porcine Cytokine/Chemokine (magnetic) kit # PCYTMG-23K-13PX (Millipore), according to the 
manufacturer’s instructions. Experiments were performed in triplicate. The kit enables a 
simultaneous multiplex analysis of 13 pig cytokines/chemokines/interleukins (GM-CSF, IFN-γ, IL-
1α, IL-1β, IL-1Rα, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-18, TNF-α) in a 25-μL aliquot of porcine cell 
culture supernatant at passage 3. 
2.11. Statistical Analysis 
All statistics were calculated using Origin 7.0 SR0 Software (OriginLab, Northampton, MA, 
USA). Data are presented as mean ± standard deviation (SD). To determine statistical significance of 
the behavioral, electrophysiological, and morphometric data between experimental groups, which 
included different numbers of animals, we used nonparametric methods for testing whether samples 
originate from the same distribution. A one-way analysis of variance (ANOVA) with Tukey’s test or 
two-way analysis of variance (ANOVA) were used in this study for multiple comparisons between 
tested groups. All analyses were performed in a blinded manner with respect to the treatment group. 
A value of p < 0.05 was considered statistically significant. 
3. Results 
3.1. Characterization of Rat Mesenchymal Stem Cells 
Analyses of the expression of surface markers in primary cultures of AD-MSCs, BM-MSCs, and 
DPMSCs, native and transduced with LV-EGFP, by flow cytometry were performed (Таble 2). The 
expression of CD34 and CD45 were below the threshold <2% in all obtained cell cultures. The 
expression of CD90 and CD73, considered to be predominant MSC markers, were highest in AD-
MSCs 99.9 ± 0.17%/98.6 ± 2.3% and 94 ± 0.5%/87.5 ± 4.4%, respectively. The level of CD90 expression 
was greater than 90% for all tested cultures, however, a significantly lower (p < 0.05) value was found 
in native and transduced by LV-EGFP DPMSCs compared to AD-MSCs and BM-MSCs. BM-MSCs 
and DP-MSCs cultures had reduced expression of CD29 (p < 0.05) compared to AD-MSCs. CD44 
expression was significantly reduced (p < 0.05) in cultures of both native and transduced LV-EGFP 
DP-MSCs compared to BM-MSCs and AD-MSCs. It should be noted that transduction by LV-EGFP 
AD-MSCs, BM-MSCs, and DP-MSCs did not lead to significant changes in the expression of the tested 
markers. 
Тable 2. Flow cytometry data on the expression of surface antigens in cells derived from rat adipose 
tissue, bone marrow, and tooth pulp before/after transduction by LV-EGFP (%). 
Source of MSC Thy-1 (CD90) CD73 CD44 CD29 
Adipose tissue  99.9 ± 0.17/98.6 ± 2.3 94 ± 0.5/87.5 ± 4.4 98.4 ± 2.9/98.7 ± 2.6 88 ± 4/80 ± 8.5 
Bone marrow 98.9 ± 1.6/96.8 ± 5.8 91 ± 0.5/88 ± 4 90.6 ± 5.8/93 ± 11.3 59 ± 7.3/51 ± 9 * 
Dental pulp 91 ± 0.5/88.5 ± 1.2 *# 87.7 ± 1.7/87 ± 8 74 ± 0.5/69 ± 9*# 49 ± 5.3/44 ± 0.5* 
* p < 0.05 as compared with analogically samples of AD-MSCs cultures, # p < 0.05 as compared with 
analogically samples of BM-MSCs cultures. 
3.2. Distribution and Survival of MSCs in the Area of SCI in Rats 
A comparative analysis of the migration and viability of AD-MSCs, BM-MSCs, and DP-MSCs 
transplanted into the area of SCI was conducted. In the spinal cord of rats, transplantation of 
transduced by LV-EGFP AD-MSCs, BM-MSCs, and DP-MSCs produced specific fluorescence up to 5 
mm rostrally and caudally from the injury site up to 60 days after cells were applied. 
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At days 7 and 14, labeled EGFP AD-MSCs, BM-MSCs, and DP-MSCs were predominantly 
located in DREZ, CC, and lateral CST (Figure 2A–F) and single fluorescent cells were present in the 
dorsal CST. There was no significant difference in the number and distribution of fluorescent MSCs 
between the experimental groups at these time points. At days 30 and 60, labeled EGFP cells were 
also found in the VH and VF (Figure 2G–L). Treated animals showed tropism of transplanted MSCs 
to the gray matter and their preferential migration through dorsal roots of the spinal cord; this can 
be attributed to directional paths for their movement and the effect of the SCI as disruptive barrier in 
this area [32]. The distribution of MSCs in the SCI area was similar for all three experimental groups. 
No significant differences were found between the experimental groups in regard to the number 
of fluorescent cells in the white and gray matter in the early periods after SCI. At days 30 and 60, both 
rostrally and caudally from the injury, the FM + DP-MSCs group showed a decrease in the number 
of EGFP-labeled cells of ~4.1-fold (p < 0.05) in VH (Figure 2M–P) and their absence in CC compared 
to groups with AD-MSCs and BM-MSCs was detected. 
 
Figure 2. Distribution and survival of MSCs encapsulated in FM after application into the area of SCI 
in rats (red box) and pigs (blue box). MSCs predominantly migrate through the posterior roots of the 
spinal cord. In the early periods (7–14 days post-transplantation) labeled by LV-EGFP (green) AD-
MSCs, BM-MSCs, and DP-MSCs were located mainly in (A–C) DREZ and (D–F) central canal (CC) in 
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rats. During late periods (30–60 days post-transplantation) labeled LV-EGFP cells were also observed 
in the (G–I) ventral horns (VH) and (J–L) ventral funiculi (VF) in rats. The A–L areas marked with a 
dashed boxed correspond to enlarged images A’–L’. Number of EGFP+-cells at days (M,N) 30 and 
(O,P) 60 at 4 mm rostrally and caudally from the injury site in VH of experimental groups with MSCs 
transplantation. At day 14, LV-EGFP MSCs (green) were mainly located in the area of DREZ, (Q) 
dorsal funiculi (DF), (R) dorsal horns (DH), and (S) CC in pigs. The Q and R areas marked with a 
dashed boxes correspond to enlarged images Q’ and R’, respectively. (T) MSCs distribution can be 
seen in the area of epidural fibrosis (gray line above spinal cord longitudinal section) according to the 
distance from injury site. MSCs were also detected in the area of epidural fibrosis, where more MSCs 
were found above the epicenter of injury and in the caudal direction, and less in the synechias above the 
rostral part of spinal cord. Asterisk indicates CC. Color dashed boxes (brown—rostral part; blue—
epicenter of injury; green—caudal part) in scheme indicate corresponding area with MSCs distribution. 
Nuclei are stained with DAPI (blue). Scale bars: (A–L) 20, (H’) 10, and (A’–G’,I’–J’–L’) 5 μm; (Q,R) 50, 
(S) 20 and (Q’,R’,T’,E’, brown and green dashed boxes) 10 μm. 
3.3. Behavioral Results in Rats 
A comparative assessment of locomotor activity after application of AD-MSCs, BM-MSCs, and 
DP-MSCs was performed using the open-field BBB locomotor rating scale. Previously, we observed 
on week 11 after SCI, the motor function scores were higher in groups with AD-MSCs (17.1 ± 3.1) 
compared to the control (FM only) group [7].. Significant differences (p < 0.05) between AD-MSCs 
and control FM group were also seen during weeks 4–11 postinjury and between AD-MSCs and BM-
MSCs at 4–6 weeks postinjury (Figure 3A). During the last 4 weeks of the study, an increase (p < 0.05) 
of the BBB scores in groups treated with DP-MSCs compared to control FM group (Figure 3B) was 
detected. The lowest results on locomotor recovery among the experimental groups were found after 
treatment with BM-MSCs, where the average BBB score in rats was higher (p < 0.05) at 3 and 9 weeks 
postinjury and did not change significantly on week 11 compared to the control group with FM 
application only (Figure 3A). These findings suggest recovery of motor function following treatment 
with FM-embedded MSCs obtained from all three sources. 
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Figure 3. Behavioral and electrophysiological studies after SCI in experimental groups of rats. BBB 
locomotor scores of rats of the FM only (blue line), FM + BM-MSCs + LV-EGFP (green line), and FM 
+ DP-MSCs + LV-EGFP (purple line) groups (A,B). The motor function scores were significantly 
higher after AD-MSCs and DP-MSCs application than those in the FM group 8 and 4 weeks 
postinjury, respectively. The lowest results in locomotor recovery between groups with MSC therapy 
were shown after application of BM-MSCs, where average BBB scores were higher at 3 and 9 weeks 
postinjury and not significantly different on week 11 compared to control group. * p < 0.05 as 
compared with the control group (FM), one-way ANOVA followed by a Tukey’s post hoc test. 
Schematic illustration of electrodes positions in rats (C). Amax of M- (D) and H-wave (E), threshold 
of M- (F) and H-waves (G), LP of M- (H) and H-waves (I), H/M wave amplitude ratio (J), LP (K) and 
Amiddle (L) of lumbar N1 after SCI in the experimental groups (X axis). At day 74 after SCI, the 
positive dynamics of the ratio Hmax/Mmax responses restoration was marked in groups with AD-
MSCs and DP-MSCs application. At the same time, there was a decrease in Amax of N1 in the FM 
only group. * p < 0.05; ** p < 0.01; # p < 0.05 as compared with intact control and experimental group 
treated with AD-MSCs (one-way ANOVA followed by a Tukey’s post hoc test). Electrophysiology 
results demonstrate motor evoked potentials (MEPs) before SCI (M) and on week 11 in FM (N), 
FM+BM-MSCs+LV-EGFP (O), FM+AD-MSCs+LV-EGFP (P), and FM+DP-MSCs+LV-EGFP (R) 
groups.3.4. Electrophysiological Findings. 
3.4. Rats 
M- and H-responses were recorded and the following parameters were evaluated across 
experimental groups: threshold, latency period (LP), maximum amplitude of the responses (Amax), 
and the ratio of H-wave Amax and M-wave Amax (Hmax/Mmax) (Figure 3C–J). At day 74, in the group 
treated with AD-MSCs, a statistically significant increase of Amax (p < 0.05) compared to intact control 
and FM + BM-MSCs treated animals was found (Figure 3D). Previously, we hypothesized that the 
application of AD-MSCs would increase the number of muscle fibers. However, the morphometry of 
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the calf muscles did not reveal any significant changes in the number of muscle fibers between the 
control and experimental groups [7]. 
H-response was absent in intact rats in 33% of cases [41] and in groups treated with AD-MSCs, 
BM-MSCs, and DP-MSCs H-response was absent in 40, 37.5, and 25% of cases, respectively. At the 
same time, in the control group with FM application only, the H-response was recorded in all cases, 
indicating facilitation of monosynaptic circuit following injury, which could be partially inhibited by 
supralisional influences in control and treated animals. At day 74 after SCI, the LP of H-wave 
remained unchanged in all investigated groups and a positive trend in the recovery (p < 0.05) of the 
Hmax/Mmax response rate was found in groups with AD-MSCs and DP-MSCs (Figure 3J), which could 
reflect the recovery from spinal shock. 
In intact rats, MEPs were recorded with an average amplitude 17.66 ± 5.30 mV and latency 5.81 
± 0.63 ms (Fig.3M). In the experimental groups, most of the animals showed bilateral MEPs, although 
in two rats MEPs were found only on one side. The average amplitude and latency values registered 
by MEPs in the experimental groups are presented in Table 3. In general, in groups treated with 
MSCs, a better recovery of the electrophysiological parameters was observed compared to the control 
group treated with FM only (Figure 3N–R). Comparing the ratio of the amplitude of the M-response 
to MEPs, all experimental groups with SCI were significantly different from the intact control, which 
is a sign of incomplete recovery. At the same time, the best indicators of MEPs recovery were noted 
in the groups with application AD-MSCs and BM-MSCs compared to other groups with SCI. 
Table 3. Results of transcranial electrical stimulation in rats. 
Groups of 
Animals 
Amplitude of 
MEPs (mV) 
Latency of 
MEPs (ms) 
Lack of MEPs in Both 
Legs (in % of Rats) 
Registration of MEPs from One 
Leg (in No. of Rats) 
Intact control 17.66 ± 5.30 5.81 ± 0.63 - - 
FM 0.5 ± 0.36 15.83 ± 1.14 44% 1 
FM + AD-MSCs + 
LV-EGFP 
1.57 ± 0.88 14.08 ± 3.83 20% 1 
FM + BM-MSCs + 
LV-EGFP 
1.68 ± 0.7 14.77 ± 3.2 32% - 
FM + DP-MSCs + 
LV-EGFP 
1.01 ± 0.75 12.85 ± 3.10 32% - 
SEPs in intact rats from the lumbar level were presented by P1–N1–P2 complex, with the largest 
in amplitude peak N1. In intact control, average value of Amiddle for peak N1 was 16.72 ± 8.68 μV; the 
average value for LP was 3.08 ± 0.97 ms (Figure 3K,L). N1–P1–N2–P2 complex (where N2 and P2 
could be not registered in normal rats) was recorded with electrodes located on the scalp and Amiddle 
and LP values of the N1 and P1 peaks were measured as well. An average value of Amiddle for the peak 
of N1 in intact control was 3.11 ± 0.60 μV and the average value for LP was 7.85 ± 0.61 ms. An average 
value of Amiddle for the peak of P1 in intact control was 4.65 ± 1.87 μV and the average value for LP 
was 14.65 ± 1.27 ms. The complex, recorded from the lumbar level, remained intact in all groups with 
SCI. However, there was a significant decrease of the Amiddle of N1 (p < 0.05) in animals treated with 
FM only compared to intact control and group treated with AD-MSCs. The expected origin of peaks 
recorded from the lumbar region are the spinal roots and neurons of the posterior horns of the lumbar 
and sacral segments of the spinal cord. SCI at the thoracic level could affect these structures via edema 
and secondary circulatory changes, which could lead to a decrease in the Amiddle of the lumbar peak. 
The absence of these changes in the group treated with AD-MSCs suggests the positive effect of AD-
MSCs. In contrast to the TES results, there was practically no recovery of scalp SEPs. We were able to 
register scalp SEPs only in one rat in the group with application AD-MSCs. 
3.5. Spinal Cord Morphometry in Rats 
Previously, we observed that application of AD-MSCs leads to improvement of morphometric 
characteristics at day 60 after cell therapy, compared to the control (FM only) group: the area of 
spared tissue was larger at distances of 1 and 2 mm rostrally and 3 mm caudally from the injury 
epicenter (p < 0.05); the total area of abnormal cavities was less at a 1 mm distance rostrally and 1–3 
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mm caudally from the injury epicenter (p < 0.05) [7]. At the same time, experimental groups treated 
with BM-MSCs had no significant difference from the control (FM only) group within 5 mm in rostral 
and caudal directions (Figure 4A,C,E). After application DP-MSCs, the total area of abnormal cavities 
was significantly less at a distance of 1 mm caudally from the injury epicenter compared to the control 
(FM only) group (Figure 4B,D,E). A significant difference in the spared tissue was found between the 
groups treated with MSCs within an area 2 mm rostrally and 3 mm caudally from the injury epicenter. 
Based on earlier results and new data, we concluded that difference was greater in the FM + AD-
MSCs group compared to FM + BM-MSCs. At 2 mm rostrally and 3.5 mm caudally from the injury 
epicenter, this difference was again greater in the FM + AD-MSCs group compared to FM + DP-MSCs. 
The total area of abnormal cavities in the group treated with AD-MSCs was smaller (p < 0.05) compared 
to BM-MSCs treated animals within the epicenter of injury and at a distance of 3 mm caudally from it; 
there was no significant difference with DP-MSCs group at all tested spinal cord regions. 
 
Figure 4. Spinal cord morphometry in experimental groups of rats. (A,B) An area of the spared tissue 
and (C,D) a total area of abnormal cavities, 5 mm rostrally and caudally from the injury epicenter at 
60 day after treatment with FM (blue line), FM + BM-MSCs + LV-EGFP (purple line) or FM + DP-MSCs 
+ LV-EGFP (green line). * p < 0.05, one-way ANOVA followed by a Tukey’s post hoc test. (E) Cross-
sections of the injured spinal cord at 74 day after SCI in experimental groups at a distance of 1 mm 
rostrally and caudally from the injury epicenter. Azur-eosin staining. Previously obtained results in 
FM + AD-MSCs + LV-EGFP group are available in our article [7]  
3.6. Assessment of Astroglial and Microglial Cells in the Area of SCI in Rats 
Using pan markers GFAP and Iba1 for astrocytes and microglia we produced a semiquantitative 
estimation of the cells in the areas of gray and white matter in spinal cord at a distance of 5 mm 
rostrally and caudally from the injury epicenter in all experimental groups (Figure 5). Astroglial 
activation was prominent (p < 0.05) in groups treated with BM-MSCs at a distance of 5 mm rostrally 
from the injury epicenter in comparison with other experimental groups in VH, CC, and DREZ 
(Figure 5A). At the same time, in the rostral direction we did not find significant differences in total 
intensity of GFAP between FM + AD-MSCs, FM + DP-MSCs, and FM treated groups, except VF for 
FM + DP-MSCs and FM groups (p < 0.05). In the caudal direction from the injury epicenter, differences 
between experimental groups in the level of GFAP expression were more prominent (Figure 5B). 
Significant changes between groups were observed in all investigated areas except VF. However, 
astroglial activation was more pronounced in the control (FM only) group and less pronounced in 
the group treated with FM + BM-MSCs. The total intensity of GFAP was least in the group treated 
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with AD-MSCs, where in the regions of CC and DREZ this value was less (p < 0.05) compared to 
intact controls (Figure 5B,C). 
Microglial activation was markedly upregulated after SCI primary at a distance of 5 mm 
caudally from the injury epicenter (Figure 5D). Peak values of the total intensity of Iba1 in grey matter 
VH and DREZ were detected in groups treated with FM + BM-MSCs or FM only. In white matter 
areas CST and VF, the total intensity of Iba1 was higher (p < 0.05) in all experimental groups compared 
to intact control (Figure 5D,E). 
3.7. Analysis of mRNAs Expression in the Area of SCI in Rats 
We performed qRT-PCR on sections obtained from the injury site at 74 day after SCI for all 
experimental groups (Figure 6). After SCI, increased expression of neurotrophic factor mRNA such 
as Fgf2, Vegf, and Ngf was observed in all experimental groups. Application of AD-MSCs led to the 
largest increase in mRNA expression of Fgf2 and application of DP-MSCs lead to the largest increase 
in Vegf (p < 0.05), compared to other experimental groups. Variations in expression of neural cell 
marker mRNAs in injured spinal cords were found. These results demonstrate that the Gfap and Iba1 
mRNA expression was similar to those described previously using immunohistochemical analysis. 
We also observed increasing mRNA expression of myelin-related proteins such as Mbp and Mpz; the 
highest levels were found in AD-MSCs treated animals. The mRNA expression of Pdgfβr and Gap-43 
were markedly upregulated (p < 0.05) after AD-MSCs and DP-MSCs application when compared to 
other experimental groups and the intact control. Our results also demonstrate that the mRNA 
expression of vital antiapoptotic regulator Hspa1b was markedly upregulated in groups treated with 
MSCs, with the highest expression within the group treated with FM + DP-MSCs (p < 0.05). 
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Figure 5. Assessment of astroglial and microglial activation at the site of injury in rats. The total 
intensity of (A,B) GFAP and (D) Iba1 (Y-axis) in the examined regions of the intact spinal cord (white 
column) or 60 day after treatment with FM only (black column), FM + AD-MSCs + LV-EGFP (violet 
column), FM + BM-MSCs + LV-EGFP (blue column), and FM + DP-MSCs + LV-EGFP (green column). 
* p < 0.05; # p < 0.05; and ## p < 0.05 as compared with all investigated groups, except FM and DP-
MSCs; one-way ANOVA followed by a Tukey’s post hoc test. (C,E) Visualization of astroglial and 
microglial activation using GFAP (yellow) and Iba1 (yellow) 5 mm caudally from the injury epicenter 
within the CC and CST in the investigated groups. Nuclei are DAPI-stained (blue). Scale bar: 25 μm. 
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Figure 6. Analysis of mRNA expression in the area of SCI in rats. Gfap, Fgf2, Hspa1b, CNPase, Pdgfβr, 
S100, Vegf, Ngf, Olig2, Caspase 3, Mbp, Gap-43, Pdgfαr, Iba1, Mpz, and Vimentin mRNA expression in 
intact spinal cord (white column) and 60 days after FM (black column), FM + AD-MSCs + LV-EGFP 
(purple column), FM + BM-MSCs + LV-EGFP (blue column), or FM + DP-MSCs + LV-EGFP (green 
column) application. The mRNA expression levels in the intact spinal cord were considered as 100%. 
* p < 0.05; # p < 0.05 as compared with all investigated groups, except DP-MSCs; ## p < 0.05 as compared 
with all investigated groups, except AD-MSCs, one-way ANOVA followed by a Tukey’s post hoc test. 
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3.8. Summary of Results from Rodent Model 
Results described above suggest that application of AD-MSCs combined with FM in the 
subacute period stimulates post-traumatic regeneration to a greater extent compared to therapy with 
BM-MSCs and DP-MSCs. This conclusion is confirmed by: (1) recovery of locomotor activity and 
nerve fiber conduction obtained by electrophysiological data; (2) tissue sparing and reduction of post-
traumatic cavitation; and (3) modulation of microglial and astroglial activation. Next, we tested the 
effect of AD-MSCs therapy in subacute period of SCI in large animals (pigs). Approximations for the 
degree of injury and experimental conditions were estimated to represent those used in rodents as 
closely as possible to allow for comparative assessment. 
3.9. Characterization of Pig Mesenchymal Stem Cells Obtained from Adipose Tissue 
The adherent cells in the primary culture were located singularly or in small groups at days 1–2 
after seeding. On the 2 day of cultivation, the cells began to divide, forming islets. All cells were 
similar in morphology, being small in size and having an elongated (fibroblast-like) shape, in most 
cases with several processes. With further cultivation, the cells spread over the bottom of a culture 
flask and increased in size, whilst preserving the fibroblast-like morphology, a typical MSC 
morphology. As the number of cells in a culture increased, their processes became more closely 
adjoined to each other and the borders of individual cells were difficult to distinguish. Cultured cells 
were maintained for at least six passages. 
Based on flow cytometry (before and after transduction), the expression of the following markers 
was determined: Thy-1 (CD90), 94.5 ± 3.7%/93.6 ± 5.2%; CD73, 92 ± 2.5%/91 ± 0.5%; CD44, 86.7 ± 
8.9%/78 ± 4%; and CD29, 63 ± 9.5%/52.6 ± 13.5%. The expression of surface antigens CD34 and CD45 
were not detected in AD-MSCs. 
3.10. MSCs Cytokine Profile in Pig 
Prior to autologous transplantation, AD-MSCs were labeled with GFP. In order to determine 
any changes in the secretory phenotype of AD-MSCs as a result of being transduced to express LV-
EGP, we performed simultaneous multiple cytokine and chemokine analysis using xMap Luminex 
Bead-Based Multiplex Assays in the supernatant from porcine AD-MSC cultures before and after 
transduction with LV-EGFP (Table 4). We did not observe significant changes in the expression of 
the investigated markers in AD-MSCs after transduction by LV-EGFP. 
Table 4. The AD-MSCs (left columns) and AD-MSCs + LV-EGFP (right columns) supernatant 
cytokine/chemokine concentrations (ng/mL). 
Cytokine/ 
Chemokine 
Pig 1 Pig 2 Pig 3 Pig 4 Pig 5 
GM-CSF <0.009/<0.009 <0.009/<0.009 
<0.009/0.01 ± 
0.0005 <0.009/<0.009 <0.009/<0.009 
IFN-g <0.12/<0.12 <0.12/<0.12 <0.12/<0.12 
1.4 ± 0.1*/1.33 ± 
0.15* 
1.2 ± 0.05 */<0.12 
IL-1a 
0.008 ± 0/0.009 ± 
0.0005 
0.008 ± 0/0.008 ± 0 0.009 ± 0/0.008 ± 0 
0.009 ± 0.0005/0.008 
± 0 
0.008 ± 0/0.008 ± 0 
IL-1b 0.01 ± 0/0.01 ± 0 
0.01 ± 0.0005/0.01 
± 0 
0.01 ± 0/0.009 ± 
0.001 
0.009 ± 0/0.01 ± 0 0.009 ± 0.0005/0.01 ± 0 
IL-1Ra <0.03/<0.03 <0.03/<0.03 <0.03/<0.03 <0.03/<0.03 <0.03/<0.03 
IL-2 <0.01/<0.01 <0.01/<0.01 <0.01/<0.01 <0.01/<0.01 <0.01/<0.01 
IL-4 <0.05/<0.05 <0.05/<0.05 <0.05/0.05 ± 0.005 <0.05/0.03 ± 0.005 <0.05/<0.05 
IL-6 
2.77 ± 0.1 */2.5 ± 
0.05 * 
0.15 ± 0 */0.15 ± 
0.01 * 
9.21 ± 0.3 */9.4 ± 
0.2 * 
0.48 ± 0.01*/0.49 ± 0* 0.57 ± 0.05 */0.62 ± 0 * 
IL-8 
21.05 ± 0.5 */20.5 ± 
0.8 * 
0.21 ± 0.01 */0.22 
± 0 * 
14.55 ± 0.3 */15 ± 
0.1 * 
4.56 ± 0.2 */4.6 ± 0.05 
* 
3.02 ± 0.05 */3.2 ± 0.1 * 
IL-10 <0.009/<0.009 <0.009/<0.009 <0.009/<0.009 0.01 ± 0.0005/<0.009 0.01 ± 0.0005/<0.009 
IL-12 <0.03/<0.03 <0.03/<0.03 <0.03/0.03 ± 0.005 <0.03/0.03 ± 0.005 <0.03/<0.03 
IL-18 0.1 ± 0 */0.1 ± 0 * 
0.08 ± 0.001/0.09 ± 
0 
0.09 ± 0.001/0.09 ± 
0 
0.17 ± 0.02 */0.2 ± 0 * 0.35 ± 0 */0.4 ± 0.05 * 
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TNF-a 0.01 ± 0/0.01 ± 0 
0.01 ± 0.0005/0.01 
± 0 
0.01 ± 0/0.01 ± 
0.005 
0.01 ± 0/0.01 ± 0.005 0.01 ± 0.0005/0.01 ± 0 
* p < 0.05 as compared with analogic samples of another pigs (AD-MSCs and AD-MSCs + LV-EGFP, 
accordingly). For values preceded with <, protein concentrations below the specified value cannot be 
detected with the kit. 
3.11. Distribution and Survival of MSCs Transplanted into the Area of SCI in Pigs 
We analyzed the behavior of MSCs at 14 days after application into the site of SCI in pigs and 
obtained results similar to those determined in the rat model. At this time, the cells were 
predominantly located in the area of DREZ, dorsal horns (DH), dorsal funiculi (DF), and CC (Figure 
2Q–S). We noted that the synechias (epidural fibrosis) in pigs is more pronounced than in rats. In this 
regard, we also detected EGFP-labeled AD-MSCs in the area of epidural fibrosis, where more MSCs 
were found above the epicenter of injury and in the caudal direction, and less in the synechias above 
the rostral part of spinal cord (Figure 2T). 
3.12. Behavioral and Electrophysiology Results in Pigs 
During the first week after SCI in pigs, no active hindlimb movements were observed, which 
corresponds to a score of 1 using the PTIBS scale (Figure 7A). At 6 weeks, before the application of 
FM only or FM + AD-MSCs, the animals had a score of 1.6 ± 0.5 (Supplementary Video S1). Over the 
next 16 weeks after reoperation, an increase of PTIBS scores, with the largest values in the group 
treated with AD-MSCs, was found. However, these differences were not statistically significant and 
at 22 weeks after SCI, the PTIBS scores in the FM only and FM + AD-MSCs groups were 4.2 ± 0.8 and 
3 ± 1.8, respectively. 
 
Figure 7. Behavioral and electrophysiology results in pigs. (A) PTIBS locomotor scores of pigs of the 
FM (blue line) and FM + AD-MSCs + LV-EGFP (red line) groups. Significant differences between the 
experimental groups throughout the experiment were not found. Electrophysiology results 
demonstrate SEPs (B) before SCI (reproducible peaks from lumbar and scalp electrodes) and (C) after 
15 min after SCI (reproducible peaks of lesser amplitude from lumbar electrodes only). (D,E) At 22 
Biomolecules 2019, 9, 811 20 of 28 
 
weeks, in the control group with FM application, only one pig had a peak from lumbar enlargement 
on one side. (F) While in the experimental group with FM + AD-MSCs application, cortical peaks on 
one side and peaks from lumbar enlargement on both sides were recorded in one pig. MEPs from the 
tibialis anterior muscle in pigs (G) before SCI and after 22 weeks in groups with (H) FM and (I) AD-
MSCs application with registration of MEPs on one side. 
Electrophysiological data (M-response, MEPs, and SEPs) were recorded before the injury, at 15 
min and at 6 and 22 weeks after SCI. No significant differences in the amplitude and latency of the M-
response before and after the injury were found suggesting that the SCI at the thoracic level is not 
affecting motor neurons and motor axons of the lumbar segments. All animals before and after SCI (15 
min) were evaluated for MEPs and SEPs (Figure 7B,C,G). At 6 weeks after SCI, no MEPs and scalp SEPs 
were recorded, with the exception of a single animal for which SEPs could be recorded from lumbar 
electrodes. These changes showed the absence of conduction along the lateral and posterior columns of 
the spinal cord, which indicated the adequacy of the injury model [42]. The absence of SEPs from the 
lumbar electrode in the majority of animals may indicate the spread of the SCI in the caudal direction. 
Across all experimental groups, no difference in restoration of conductivity along the lateral 
columns was found; in the control group treated with FM only after 22 weeks only one pig had MEPs 
on one side (Figure 7H); and in the experimental group treated with FM + AD-MSCs during the same 
period MEPs were recorded in two pigs on one side (Figure 7I). 
The main differences found relate to the ascending pathway of deep sensitivity of the spinal 
cord. At 22 weeks, in the control group with FM-only application, scalp SEPs were not found, and 
only one pig had a peak from lumbar enlargement on one side (Figure 7D,E). While in the 
experimental group treated with FM + AD-MSCs, cortical peaks on one side and peaks from lumbar 
enlargement on both sides were recorded in one pig (Figure 7F) and lumbar peaks were recorded on 
one side in two pigs. Thus, we can state the partial restoration of the somatosensory ways in three 
out of five pigs treated with FM + AD-MSCs. 
3.13. Spinal Cord Morphometry in Pigs 
We observed significant difference in the areas of the spared tissue and abnormal cavities 
between the experimental groups (Figure 8). AD-MSCs application led to improvement of 
morphometric characteristics at 16 weeks after therapy compared to the control (FM only) group. The 
area of spared tissue was higher at a distance of 2 mm rostrally and 1–3 mm caudally from the injury 
epicenter (p < 0.05) and the total area of abnormal cavities was less at a distances of 2 and 4 mm 
rostrally from the injury epicenter (p < 0.05) (Figure 8A–С). 
3.15. Assessment of Astroglial and Microglial Cells in the Area of SCI in Pigs 
At 22 weeks after SCI, the level of GFAP expression in the FM only and FM + AD-MSC treated 
groups increased in comparison with intact control (Figure 8D). We observed significant difference 
between the control FM group and the FM + AD-MSCs group in DREZ caudally from the injury 
epicenter, where value of the total intensity of GFAP was more than 2-fold higher (p < 0.05) in FM 
control group (Figure 8D,E). After FM application, there were higher levels (p < 0.05) of GFAP 
expression relative to the intact controls in the VF and CC caudally from the injury epicenter, while 
the FM + AD-MSCs group showed no significant differences in analogical areas when compared with 
intact control or FM only treated pigs (Figure 8D,E). 
Microglial activation was upregulated after SCI in experimental groups in DREZ at a distance 
of 5 mm caudally from the injury epicenter; a significant difference (p < 0.05) was identified between 
the FM-only group and intact control (Figure 8F,G). Iba1+-microglia in DREZ were mainly visualized 
as cell clusters in groups with SCI compared to intact control, in which microglia were distributed 
more evenly. 
Biomolecules 2019, 9, 811 21 of 28 
 
 
Figure 8. Spinal cord morphometry and assessment of astroglial/microglial activation at the site of 
injury in pigs. (A) An area of the spared tissue and (B) a total area of abnormal cavities, 5 mm rostrally 
and caudally from the injury epicenter in 16 weeks after FM (blue line) and FM + AD-MSCs + LV-
EGFP (yellow line) application. * p < 0.05, one-way ANOVA followed by a Tukey’s post hoc test. (C) 
Cross-sections of the injured spinal cord 22 weeks after SCI in experimental groups at the distances 
of 5 mm rostrally and caudally from the injury epicenter. Azur-eosin staining. The total intensity of 
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(D) GFAP and (F) Iba1 (Y-axis) in intact spinal cord (white column) or 16 weeks after FM (black 
column) and FM + AD-MSCs + LV-EGFP (violet column) application in the examined regions. * p < 
0.05 as compared with all investigated or indicated groups, one-way ANOVA followed by a Tukey’s 
post hoc test. (F’) Schematic representation of the investigated areas. (E,G) Visualization of astroglial 
and microglial activation using GFAP (yellow) and Iba1 (yellow) 5 mm caudally from the injury 
epicenter within the DREZ and VF in the investigated groups. Nuclei are DAPI-stained (blue). Scale 
bar: 50 μm. 
4. Discussion 
Experimental approaches for the treatment of SCI have been evolving and currently include a 
variety of approaches with a significant prevalence of genetic [43–45] and cellular therapies. Cells of 
adult organism, embryonic cells, and induced pluripotent stem cells have been used in multiple 
studies with variable effects [46–48], as has the application of extracellular vesicles as a cell-free therapy 
[49]. In the context of safety and practical capacity of translation into the clinic, MSCs appear to be the 
most promising therapy at the current time [50]. In addition, FM application is a widespread 
neurosurgical technique commonly used in humans. In this study, the comparative efficiency of MSCs 
derived from bone marrow, adipose tissue, and dental pulp combined with FM in the subacute period 
of SCI was evaluated for the first time comparatively across small (rat) and large (pig) animal models. 
Prior to in vivo experiments, we performed a morphological and phenotypic assessment of our 
cultivated MSCs. Results showed reduced CD29 expression in BM-MSCs and DP-MSCs cultures, as 
well as a significant reduction of CD44 expression in DP-MSCs, in comparison with AD-MSCs. 
Expression of CD29 and CD44 had previously been investigated in AD-MSCs, BM-MSCs, and DP-
MSCs; BM-MSCs showed higher expression of CD29 than DP-MSCs and AD-MSCs at the third 
passage [51]. These differences could reflect differences in the procedures used to isolate and cultivate 
MSCs and/or other biological factors. EGFP has been in routine use as a tag for in vivo model studies. 
It is considered that EGFP gene functionally is neutral when integrated and provides convenient cell 
labeling without a significant impact on basic cellular functions [52], even within MSCs [53]. We 
demonstrated that within our isolated MSCs, transduction of AD-MSCs, BM-MSCs, and DP-MSCs 
cells by LV-EGFP did not lead to significant changes in the expression of the investigated markers, 
which is consistent with other works [54]. 
The AD-MSCs applied after SCI in rats demonstrated the best results in restoring the motor 
activity (BBB score). However, it would be inaccurate to estimate the effectiveness of therapy based 
only on a behavioral test. In this regard, the summation of the data obtained from the M/H-responses, 
MEPs, and SEPs suggests the superiority of applying FM-embedded AD-MSCs compared to 
analogical application of FM-embedded MSCs obtained from other sources. Results obtained with 
BBB assessment are often deemed to be controversial as they do not account for variations in the 
underlying study design, for example, the variety of SCI models and their severity, differences in 
transplantation protocols (cell number, routes, and post-traumatic period of administration), the 
presence or absence of immunosuppression, and the quality of MSCs generated in culture. Given 
these caveats, a systematic review and meta-analysis of rat models of SCI demonstrates a difference 
in behavioral BBB locomotor score means of 3.9 in favor of treatment with MSCs [55]. 
In the present study, we found the restoration of the tissue integrity was improved with AD-
MSCs treatment. The reduction of a total area of abnormal cavities and improved tissue retention 
were reported in numerous studies of MSC transplantation in SCI [56–59]. Ryu et al. [18] compared 
the efficiency of therapy of Matrigel mixed with MSCs derived from fat, bone marrow, Wharton’s 
jelly, and umbilical cord blood in dogs with spinal compression and similarly observed the lowest 
average lesion size in the adipose-derived MSCs group. MSCs can mediate anatomical improvement 
in the subacute phase after SCI through anti-inflammatory activity, glial scar reduction, and cell 
bridging effects [50,60]. Our results suggest that MSCs are able to prevent secondary injury by 
contributing to astroglia suppression, consistent with the results of other studies of MSC 
transplantation in SCI [61–63]. We observed greater reduction of astroglial activation caudally from 
the injury epicenter after AD-MSCs application compared to other sources of MSCs and the control 
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groups. At the same time, we did not find a significant reduction of microglia pan marker Iba1 in the 
groups with MSCs transplantation. 
Our findings within the rodent SCI model encouraged us to assess the effect of AD-MSCs in the 
subacute period of SCI in large animals. We evaluated the degree of injury and assessed the efficiency 
of AD-MSCs by the same criterions as in rats and we found similar results on the migration of MSCs 
after their application into the site of SCI. Our data also show tropism of transplanted AD-MSCs to 
the gray matter and their preferential migration through dorsal roots of the spinal cord that can be 
attributed to the presence of directional paths for their movement and the disrupted barrier in this 
area after SCI. The synechias (epidural fibrosis) was more pronounced in pigs compared to rats. In 
this regard, we also detected EGFP-labeled AD-MSCs in the area of epidural fibrosis, where 
significantly less MSCs were found in the synechias above the rostral part of spinal cord. These results 
may indicate the predominant migration of MSCs is in the rostral direction from the epicenter of SCI, 
which confirms our earlier in vitro model data (unpublished observations, [64]).  
In contrast with the rodent model, we did not find a significant improvement in motor 
performance or increased behavioral scores in pigs that received treatment with AD-MSCs compared 
to the control group (FM application only). Park et al. [65] carried out intraspinal transplantation of 
MSCs derived from umbilical cord blood at 12 h and at 1 and 2 weeks after compression SCI in dogs; 
the animals receiving this therapy showed a significant increase in three different motor function 
scores after 1 week. However, application of a similar therapy, both in the acute (24 h) and delayed 
(2 weeks) period from SCI, did not lead to a motor function recovery. Similar outcomes were reported 
after intraspinal transplantation of Matrigel mixed with AD-MSCs, previously induced into neuronal 
differentiation at one week after SCI [66]. The electrophysiological changes observed in our study of 
pigs suggest that FM + AD-MSCs may have a positive effect on the restoration of long spinal cord 
tracts. These results are consistent with other studies that show improvement in SEPs in dogs and 
pigs with compression SCI after UCB-MSCs and BM-MSCs intraspinal injection [67,68]. Our results 
also suggest that application of AD-MSCs embedded in FM affects primarily distal to the injury site 
region of the spinal cord, although without significant restoration of conductivity across spinal tracts. 
Similar to results in rats, application of AD-MSCs embedded in FM at the SCI site in pigs 
facilitated restoration of neural tissue integrity, as confirmed by morphometric analysis. The 
reductions of cavity formation and fibrosis after MSC transplantation in a large animal models of SCI 
were reported previously [65–68]. The identification of astroglial activation in pigs supports the 
capacity of AD-MSCs to reduce GFAP expression predominantly in the caudal direction from the 
epicenter of injury, similar to what we found in rats although to a lesser degree. The potential 
reduction in astroglial activation was attributed to the ability of MSCs to decrease cyclooxygenase-2 
and IL-6 cytokine levels [18,59] and secretion of TNF-stimulated gene-6 [69–72], which consequently 
decreases NF-κB signaling, resulting in modulation of А1 neuroinflammatory reactive astrocytes 
[73,74]. We found no effect of AD-MSCs treatment on microglial activation in pigs, similar to results 
in rats. In addition, significant differences in Iba1+-microglia behavior in DREZ after SCI were found 
in both rats and pigs. In pigs, Iba1+-microglia in DREZ were mainly visualized as a compact cell 
clusters compared to pig intact control and in rats where the microglia were distributed more evenly. 
It was reported that clusters of activated microglia are formed mainly in the areas of active 
demyelination of white matter near the areas of active tissue damage in the brain of patients with 
multiple sclerosis and this specific microglia formation was not associated with destruction of blood–
brain barrier [75]. Detected differences in microglia behavior in the area of SCI in rats and pigs have 
not previously been described and require further investigation. 
5. Conclusion 
The results of this study demonstrate that application of AD-MSCs combined with fibrin matrix 
during the subacute period in rats provides significantly higher post-traumatic regeneration 
compared to similar applications of BM-MSCs or DP-MSCs. Particularly, restoration of locomotor 
activity and conduction along spinal axons, reduction of post-traumatic cavitation, enhancing tissue 
retention, and modulation of microglial and astroglial activation were found in the rat model with 
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AD-MSCs treatment. What mediates the greater therapeutic effect of AD-MSCs in SCI compared to 
BM-MSCs or DP-MSCs remains to be fully understood. However, biological advantages in the 
proliferative capacity, cell viability under oxidative stress, secreted proteins, and 
immunomodulatory effects have been previously discussed for AD-MSCs and may be critical factors 
[23,76]. These data indicate that application of MSCs combined with fibrin matrix into the surface of 
spinal cord may be an effective and safe approach for delivering cells to the damaged area. 
Furthermore, our results from pigs demonstrate partial replication of the findings observed in rats, 
regarding partial restoration of the somatosensory spinal pathways, reduction of post-traumatic 
cavitation, enhancing tissue retention, and modulation of astroglial activation in the DREZ. 
Significant differences in functional recovery within the pig model could be attributed to the 
differences in the secretory phenotype of the transplanted cells and variable neuroregenerative 
potential of large animals. This is supported by significant differences in cytokine profile of MSCs 
obtained from different pigs; previous studies have also indicated donor-related heterogeneity of 
MSCs [77,78]. The therapeutic potential of adult neurogenesis is well recognized although the 
neuroregenerative capacity seems to be different between small and large animals and humans, 
which does not allow us to reach an optimal clinical outcome. The application of AD-MSCs 
embedded in FM at the site of SCI during the subacute period can stimulate important mechanisms 
of nervous tissue regeneration in both rats and pigs. Results in pigs confirm previous observations in 
rats and support the possible utility of AD-MSCs transplantation in large animals and in humans 
suffering subacute paraplegia. However, we need to more carefully analyze the secretory phenotype 
of donor cells, confirming how the therapeutic activity of transplanted MSCs is mediated before any 
possible clinical translation. 
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